Aubrey Capital Management Ltd Lowers Position in DexCom, Inc. (NASDAQ:DXCM)

Aubrey Capital Management Ltd lessened its stake in DexCom, Inc. (NASDAQ:DXCM) by 2.0% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 28,860 shares of the medical device company’s stock after selling 600 shares during the quarter. DexCom makes up about 1.5% of Aubrey Capital Management Ltd’s investment portfolio, making the stock its 15th largest position. Aubrey Capital Management Ltd’s holdings in DexCom were worth $3,582,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently modified their holdings of the stock. Valley National Advisers Inc. raised its stake in DexCom by 73.0% during the fourth quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock valued at $30,000 after purchasing an additional 103 shares in the last quarter. MV Capital Management Inc. raised its stake in DexCom by 99.3% during the fourth quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock valued at $34,000 after purchasing an additional 138 shares in the last quarter. Washington Trust Advisors Inc. raised its stake in DexCom by 120.6% during the fourth quarter. Washington Trust Advisors Inc. now owns 353 shares of the medical device company’s stock valued at $44,000 after purchasing an additional 193 shares in the last quarter. Turtle Creek Wealth Advisors LLC purchased a new stake in DexCom during the fourth quarter valued at $57,000. Finally, NBC Securities Inc. purchased a new stake in DexCom during the third quarter valued at $47,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently issued reports on DXCM. Royal Bank of Canada began coverage on shares of DexCom in a research note on Tuesday, March 12th. They set an “outperform” rating and a $165.00 price target on the stock. StockNews.com downgraded shares of DexCom from a “buy” rating to a “hold” rating in a research note on Tuesday. Canaccord Genuity Group increased their target price on shares of DexCom from $144.00 to $145.00 and gave the company a “buy” rating in a research note on Friday. Citigroup increased their target price on shares of DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a research note on Wednesday, April 3rd. Finally, Raymond James increased their target price on shares of DexCom from $151.00 to $160.00 and gave the company a “strong-buy” rating in a research note on Friday. Three investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $141.67.

Insiders Place Their Bets

In other DexCom news, EVP Matthew Vincent Dolan sold 1,990 shares of the firm’s stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $137.81, for a total transaction of $274,241.90. Following the completion of the transaction, the executive vice president now directly owns 42,377 shares of the company’s stock, valued at approximately $5,839,974.37. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other DexCom news, CEO Kevin R. Sayer sold 49,633 shares of the firm’s stock in a transaction that occurred on Monday, April 8th. The shares were sold at an average price of $138.30, for a total transaction of $6,864,243.90. Following the completion of the transaction, the chief executive officer now directly owns 283,893 shares of the company’s stock, valued at approximately $39,262,401.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Matthew Vincent Dolan sold 1,990 shares of the firm’s stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $137.81, for a total transaction of $274,241.90. Following the sale, the executive vice president now directly owns 42,377 shares in the company, valued at approximately $5,839,974.37. The disclosure for this sale can be found here. In the last ninety days, insiders sold 189,375 shares of company stock valued at $25,530,859. 0.41% of the stock is owned by insiders.

DexCom Trading Down 9.9 %

Shares of NASDAQ DXCM traded down $13.67 during mid-day trading on Friday, reaching $124.34. The company had a trading volume of 8,578,184 shares, compared to its average volume of 2,409,208. The business’s 50-day moving average is $131.13 and its 200-day moving average is $118.30. The company has a current ratio of 2.84, a quick ratio of 2.48 and a debt-to-equity ratio of 1.18. The stock has a market cap of $49.24 billion, a price-to-earnings ratio of 80.22, a price-to-earnings-growth ratio of 2.37 and a beta of 1.20. DexCom, Inc. has a 52 week low of $74.75 and a 52 week high of $142.00.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, April 25th. The medical device company reported $0.32 EPS for the quarter, beating the consensus estimate of $0.27 by $0.05. The firm had revenue of $921.00 million during the quarter, compared to analyst estimates of $911.20 million. DexCom had a net margin of 16.82% and a return on equity of 31.38%. Equities analysts expect that DexCom, Inc. will post 1.76 earnings per share for the current year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.